Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Toyama Chemical Co., Ltd. ' Product Pipeline Review ' 2012

201 views

Published on

Toyama Chemical Co., Ltd. ' Product Pipeline Review ' 2012 Summary Global Market Direct's pharmaceuticals report, "Toyama Chemical Co., Ltd. - Product Pipeline Review - 2012" provides data on the Toyama Chemical Co., Ltd.'s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects. This report is built using data and information sourced from Global Markets Direct's proprietary databases, Toyama Chemical Co., Ltd.'s corporate website, SEC filings, investor presentations and featured press releases, both from Toyama Chemical Co., Ltd. and industry-specific third party sources, put together by Global Markets Direct's team. Scope - Toyama Chemical Co., Ltd. - Brief Toyama Chemical Co., Ltd. overview including business description, key information and facts, and its locations and subsidiaries.- Review of current pipeline of Toyama Chemical Co., Ltd. human therapeutic division.- Overview of pipeline therapeutics across various therapy areas.- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.- Product profiles for late stage and clinical stage products of Toyama Chemical Co., Ltd. with complete description of the product's developmental history, mechanism of action, therapeutic class, target and major milestones. - Recent updates of the Toyama Chemical Co., Ltd.'s pipeline in the last quarter. - Key discontinued and dormant projects. - Latest news and deals relating to the products. Reasons to buy - Evaluate Toyama Chemical Co., Ltd.'s strategic position with total access to detailed information on its product pipeline. - Assess the growth potential of Toyama Chemical Co., Ltd. in its therapy areas of focus. - Identify new drug targets and therapeutic classes in the Toyama Chemical Co., Ltd.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas. - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps. - Exploit collaboration and partnership opportunities with Toyama Chemical Co., Ltd.. - Avoid Intellectual Property Rights related issues. - Explore the dormant and discontinued projects of Toyama Chemical Co., Ltd. and identify potential opportunities in those areas.

  • Be the first to comment

  • Be the first to like this

Toyama Chemical Co., Ltd. ' Product Pipeline Review ' 2012

  1. 1. Find Industry reports, Company profilesReportLinker and Market Statistics >> Get this Report Now by email!Toyama Chemical Co., Ltd. Product Pipeline Review 2012Published on December 2012 Report SummaryToyama Chemical Co., Ltd. Product Pipeline Review 2012SummaryGlobal Market Directs pharmaceuticals report, "Toyama Chemical Co., Ltd. - Product Pipeline Review - 2012" provides data on theToyama Chemical Co., Ltd.s research and development focus. The report includes information on current developmental pipeline,complete with latest updates, and features on discontinued and dormant projects.This report is built using data and information sourced from Global Markets Directs proprietary databases, Toyama Chemical Co.,Ltd.s corporate website, SEC filings, investor presentations and featured press releases, both from Toyama Chemical Co., Ltd. andindustry-specific third party sources, put together by Global Markets Directs team.Scope- Toyama Chemical Co., Ltd. - Brief Toyama Chemical Co., Ltd. overview including business description, key information and facts,and its locations and subsidiaries.- Review of current pipeline of Toyama Chemical Co., Ltd. human therapeutic division.- Overview of pipeline therapeutics across various therapy areas.- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities,across the globe.- Product profiles for late stage and clinical stage products of Toyama Chemical Co., Ltd. with complete description of the productsdevelopmental history, mechanism of action, therapeutic class, target and major milestones.- Recent updates of the Toyama Chemical Co., Ltd.s pipeline in the last quarter.- Key discontinued and dormant projects.- Latest news and deals relating to the products.Reasons to buy- Evaluate Toyama Chemical Co., Ltd.s strategic position with total access to detailed information on its product pipeline.- Assess the growth potential of Toyama Chemical Co., Ltd. in its therapy areas of focus.- Identify new drug targets and therapeutic classes in the Toyama Chemical Co., Ltd.s R&D portfolio and develop key strategicinitiatives to reinforce pipeline in those areas.- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.- Exploit collaboration and partnership opportunities with Toyama Chemical Co., Ltd..- Avoid Intellectual Property Rights related issues.- Explore the dormant and discontinued projects of Toyama Chemical Co., Ltd. and identify potential opportunities in those areas.Toyama Chemical Co., Ltd. Product Pipeline Review 2012 (From Slideshare) Page 1/6
  2. 2. Find Industry reports, Company profilesReportLinker and Market Statistics >> Get this Report Now by email! Table of ContentTable of ContentsTable of Contents 2List of Tables 4List of Figures 4Toyama Chemical Co., Ltd. Snapshot 5Toyama Chemical Co., Ltd. Overview 5Key Information 5Key Facts 5Toyama Chemical Co., Ltd. Research and Development Overview 6Key Therapeutic Areas 6Toyama Chemical Co., Ltd. Pipeline Review 8Pipeline Products by Stage of Development 8Pipeline Products Monotherapy 9Pipeline Products Combination Treatment Modalities 10Toyama Chemical Co., Ltd. Pipeline Products Glance 11Toyama Chemical Co., Ltd. Late Stage Pipeline 11Registration Filed Products/Combination Treatment Modalities 11Phase III Products/Combination Treatment Modalities 12Toyama Chemical Co., Ltd. Clinical Stage Pipeline Products 13Phase II Products/Combination Treatment Modalities 13Phase I Products/Combination Treatment Modalities 14Toyama Chemical Co., Ltd. Early Stage Pipeline Products 15Pre-Clinical Products/Combination Treatment Modalities 15Toyama Chemical Co., Ltd. Drug Profiles 16favipiravir 16Product Description 16Mechanism of Action 16R&D Progress 16garenoxacin mesylate 17Product Description 17Mechanism of Action 17R&D Progress 17iguratimod 18Product Description 18Mechanism of Action 18R&D Progress 18ozenoxacin 20Product Description 20Mechanism of Action 20R&D Progress 20T-1106 22Product Description 22Mechanism of Action 22R&D Progress 22Toyama Chemical Co., Ltd. Product Pipeline Review 2012 (From Slideshare) Page 2/6
  3. 3. Find Industry reports, Company profilesReportLinker and Market Statistics >> Get this Report Now by email!T-2307 23Product Description 23Mechanism of Action 23R&D Progress 23T-5224 24Product Description 24Mechanism of Action 24R&D Progress 24T-614 + Methotrexate 25Product Description 25Mechanism of Action 25R&D Progress 25T-817MA 26Product Description 26Mechanism of Action 26R&D Progress 26Toyama Chemical Co., Ltd. Pipeline Products by Route of Administration 27Toyama Chemical Co., Ltd. Pipeline Products By Mechanism of Action 28Toyama Chemical Co., Ltd. Recent Pipeline Updates 30Toyama Chemical Co., Ltd. - Dormant Projects 32Toyama Chemical Co., Ltd. Company Statement 33Toyama Chemical Co., Ltd. Locations And Subsidiaries 34Head Office 34Other Locations & Subsidiaries 34Toyama Chemical Co., Ltd., Recent Developments 35Toyama Chemical Co., Ltd.- Press Release 35Oct 05, 2012: Ferrer Successfully Completes Absorption, Tolerability And Safety Study In Juveniles As Young As Two Months Of AgeFor New Antibacterial Compound Ozenoxacin 35Sep 11, 2012: Eisai To Launch Anti-Rheumatic Agent Careram 35Jun 29, 2012: Eisai And Toyama Chemical Receive Approval To Market Anti-Rheumatic Agent Iguratimod In Japan 36Mar 15, 2012: JPM-TMT Announces $138.5m Grant To MediVector For Development Of Influenza Drug, Favipiravir 37Jan 19, 2012: Ferrer Initiates Phase III Clinical Studies For Ozenoxacin In Development As Topical Treatment For Impetigo AndOther Infectious Dermatological Conditions 38Mar 24, 2009: Toyama Chemical And Eisai Decide to Conduct Additional Study For Anti-Rheumatic Drug T-614 38Financial Deals Landscape 39Toyama Chemical Co., Ltd., Deals Summary 39Toyama Chemical Co., Ltd., Pharmaceuticals & Healthcare, Deal Details 40Licensing Agreements 40Toyama Chemical Enters Into Licensing Agreement With Roche 40Astellas Pharma Enters Into Licensing Agreement With Toyama Chemical 42Acquisition 44Taisho Pharma Acquires Minority Stake In Toyama Chemical 44FUJIFILM Holdings Acquires 66% Stake In Toyama Chemical 46Appendix 48Methodology 48Coverage 48Secondary Research 48Primary Research 48Toyama Chemical Co., Ltd. Product Pipeline Review 2012 (From Slideshare) Page 3/6
  4. 4. Find Industry reports, Company profilesReportLinker and Market Statistics >> Get this Report Now by email!Expert Panel Validation 48Contact Us 49Disclaimer 49List of TablesToyama Chemical Co., Ltd., Key Information 5Toyama Chemical Co., Ltd., Key Facts 5Toyama Chemical Co., Ltd. Pipeline by Indication, 2013 7Toyama Chemical Co., Ltd. Pipeline by Stage of Development, 2013 8Toyama Chemical Co., Ltd. Monotherapy Products in Pipeline, 2013 9Toyama Chemical Co., Ltd. Combination Treatment Modalities in Pipeline, 2013 10Toyama Chemical Co., Ltd. Filed, 2013 11Toyama Chemical Co., Ltd. Phase III, 2013 12Toyama Chemical Co., Ltd. Phase II, 2013 13Toyama Chemical Co., Ltd. Phase I, 2013 14Toyama Chemical Co., Ltd. Pre-Clinical, 2013 15Toyama Chemical Co., Ltd. Pipeline By Route of Administration, 2013 27Toyama Chemical Co., Ltd. Pipeline Products By Mechanism of Action, 2013 28Toyama Chemical Co., Ltd. Recent Pipeline Updates, 2013 30Toyama Chemical Co., Ltd. - Dormant Developmental Projects,2013 32Toyama Chemical Co., Ltd., Other Locations 34Toyama Chemical Co., Ltd., Subsidiaries 34Toyama Chemical Co., Ltd., Deals Summary 39Toyama Chemical Enters Into Licensing Agreement With Roche 40Astellas Pharma Enters Into Licensing Agreement With Toyama Chemical 42Taisho Pharma Acquires Minority Stake In Toyama Chemical 44FUJIFILM Holdings Acquires 66% Stake In Toyama Chemical 46List of FiguresToyama Chemical Co., Ltd. Pipeline by Indication, 2013 7Toyama Chemical Co., Ltd. Pipeline by Stage of Development, 2013 8Toyama Chemical Co., Ltd. Monotherapy Products in Pipeline, 2013 9Toyama Chemical Co., Ltd. Combination Treatment Modalities in Pipeline, 2013 10Toyama Chemical Co., Ltd. Pipeline By Route of Administration, 2013 27Toyama Chemical Co., Ltd. - Pipeline Products By Mechanism of Action, 2013 28Toyama Chemical Co., Ltd. Product Pipeline Review 2012 (From Slideshare) Page 4/6
  5. 5. Find Industry reports, Company profilesReportLinker and Market Statistics >> Get this Report Now by email! Fax Order Form To place an order via fax simply print this form, fill in the information below and fax the completed form to: Europe, Middle East and Africa : + 33 4 37 37 15 56 Asia, Oceania and America : + 1 (805) 617 17 93 If you have any questions please visit http://www.reportlinker.com/notify/contact Order Information Please verify that the product information is correct and select the format(s) you require. Toyama Chemical Co., Ltd. Product Pipeline Review 2012 Product Formats Please select the product formats and the quantity you require. 1 User License--USD 1 500.00 Quantity: _____ Site License--USD 3 000.00 Quantity: _____ Corporate License--USD 4 500.00 Quantity: _____ Contact Information Please enter all the information below in BLOCK CAPITALS Title: Mr Mrs Dr Miss Ms Prof First Name: _____________________________ Last Name: __________________________________ Email Address: __________________________________________________________________________ Job Title: __________________________________________________________________________ Organization: __________________________________________________________________________ Address: __________________________________________________________________________ City: __________________________________________________________________________ Postal / Zip Code: __________________________________________________________________________ Country: __________________________________________________________________________ Phone Number: __________________________________________________________________________ Fax Number: __________________________________________________________________________Toyama Chemical Co., Ltd. Product Pipeline Review 2012 (From Slideshare) Page 5/6
  6. 6. Find Industry reports, Company profilesReportLinker and Market Statistics >> Get this Report Now by email! Payment Information Please indicate the payment method, you would like to use by selecting the appropriate box. Payment by credit card Card Number: ______________________________________________ Expiry Date __________ / _________ CVV Number _____________________ Card Type (ex: Visa, Amex…) _________________________________ Payment by wire transfer Crédit Mutuel RIB : 10278 07314 00020257701 89 BIC : CMCIFR2A IBAN : FR76 1027 8073 1400 0202 5770 189 Payment by check UBIQUICK SAS 16 rue Grenette – 69002 LYON, FRANCE Customer signature:   Please note that by ordering from Reportlinker you are agreeing to our Terms and Conditions at http://www.reportlinker.com/index/terms Please fax this form to: Europe, Middle East and Africa : + 33 4 37 37 15 56 Asia, Oceania and America : + 1 (805) 617 17 93Toyama Chemical Co., Ltd. Product Pipeline Review 2012 (From Slideshare) Page 6/6

×